Published in J Antimicrob Chemother on May 28, 2014
Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections. Open Forum Infect Dis (2015) 1.34
Antibiotic strategies in the era of multidrug resistance. Crit Care (2016) 1.23
Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections. Antimicrob Agents Chemother (2015) 0.97
Colistin and Fusidic Acid, a Novel Potent Synergistic Combination for Treatment of Multidrug-Resistant Acinetobacter baumannii Infections. Antimicrob Agents Chemother (2015) 0.96
Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother (2015) 0.91
A Review of Novel Combinations of Colistin and Lipopeptide or Glycopeptide Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii. Infect Dis Ther (2014) 0.91
Update on the Epidemiology, Treatment, and Outcomes of Carbapenem-resistant Acinetobacter infections. Chonnam Med J (2014) 0.91
Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy? Expert Opin Pharmacother (2016) 0.89
Considerations About Antimicrobial Stewardship in Settings with Epidemic Extended-Spectrum β-Lactamase-Producing or Carbapenem-Resistant Enterobacteriaceae. Infect Dis Ther (2015) 0.84
Impact of combination antimicrobial therapy on mortality risk for critically ill patients with carbapenem-resistant bacteremia. Antimicrob Agents Chemother (2015) 0.82
Three Dimensional Checkerboard Synergy Analysis of Colistin, Meropenem, Tigecycline against Multidrug-Resistant Clinical Klebsiella pneumonia Isolates. PLoS One (2015) 0.81
Efficacy of Appropriate Antimicrobial Therapy on the Survival of Patients With Carbapenem Nonsusceptible Klebsiella Pneumoniae Infection: A Multicenter Study in Taiwan. Medicine (Baltimore) (2015) 0.78
Bloodstream infections in internal medicine. Virulence (2016) 0.78
Activity of antimicrobial combinations against KPC-2-producing Klebsiella pneumoniae in a rat model and time-kill assay. Antimicrob Agents Chemother (2015) 0.77
Optimizing antimicrobial therapy in critically ill patients. Infect Drug Resist (2014) 0.77
Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review and Meta-Analysis. Medicine (Baltimore) (2016) 0.75
In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa. BMC Infect Dis (2016) 0.75
In vitro activity of tigecycline in combination with rifampin, doripenem or ceftazidime against carbapenem-resistant Klebsiella pneumoniae bloodstream isolates. J Antibiot (Tokyo) (2016) 0.75
Beyond Susceptible and Resistant, Part III: Treatment of Infections due to Gram-Negative Organisms Producing Carbapenemases. J Pediatr Pharmacol Ther (2016) 0.75
Synergistic combinations of polymyxins. Int J Antimicrob Agents (2016) 0.75
In vitro assessment of combined polymyxin B and minocycline therapy against Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae. Antimicrob Agents Chemother (2017) 0.75
Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases. Eur J Clin Microbiol Infect Dis (2016) 0.75
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis (2014) 2.65
Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet (2006) 2.32
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis (2014) 1.80
Development and validation of a multiplex PCR assay for identification of the epidemic ST-258/512 KPC-producing Klebsiella pneumoniae clone. Diagn Microbiol Infect Dis (2013) 0.92
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. PLoS One (2015) 0.79
State of the Art of Dual Therapy in 2015. AIDS Rev (2015) 0.76
Linking Sustainable Use Policies to Novel Economic Incentives to Stimulate Antibiotic Research and Development. Infect Dis Rep (2017) 0.75
Impact of Pre-Analytical Time on the Recovery of Pathogens from Blood Cultures: Results from a Large Retrospective Survey. PLoS One (2017) 0.75
Clinical Utility of Epstein-Barr Virus Viral Load Monitoring and Risk Factors for Posttransplant Lymphoproliferative Disorders After Kidney Transplantation: A Single-Center, 10-Year Observational Cohort Study. Transplant Direct (2017) 0.75
Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. J Int AIDS Soc (2014) 0.75
A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study). PLoS One (2019) 0.75
Cardiovascular disease in women with HIV-1 infection. Int J Cardiol (2017) 0.75
Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia. Int J Antimicrob Agents (2016) 0.75